DDInter826 DDInter856
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Glipizide {u} (Compound) resembles {v} (Compound) Glyburide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Glipizide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Glipizide {u} (Compound) binds {v} (Gene) ABCC8
Glipizide {u} (Compound) upregulates {v} (Gene) INPP4B
Glipizide {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonylurea Compounds
Glipizide {u} (Compound) downregulates {v} (Gene) CEBPB
Glipizide {u} (Compound) causes {v} (Side Effect) Retinal haemorrhage
Glipizide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methylcellulose
Glipizide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Glipizide (Compound) resembles Glyburide (Compound)
Glipizide (Compound) resembles Chlorpropamide (Compound)
Glipizide (Compound) treats type 2 diabetes mellitus (Disease)
Glipizide (Compound) binds ABCC8 (Gene)
Glipizide (Compound) upregulates INPP4B (Gene)
Glipizide (Compound) is included by Sulfonylurea Compounds (Pharmacologic Class)
Glipizide (Compound) downregulates CEBPB (Gene)
Glipizide (Compound) causes Retinal haemorrhage (Side Effect)
Glipizide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Glipizide may cause a minor interaction that can limit clinical effects when taken with Methyldopa